CSIRO are primarily a research organisation, Bio-Gene have certainly been leveraging their scientific expertise in producing scalable Flavocide and Qcide formulations.
Larger companies have the financial capacity and influence to fast track product registration and distribution.
Licensing is the path of least resistance for BGT.
The low cash burn and healthy cash balance is one thing shareholders can’t be disappointed by.
BGT Price at posting:
9.9¢ Sentiment: Buy Disclosure: Held
